Skip to content
Disclosery

Velan Capital Investment Management LP

Follow

13F filer, CIK 1848809, ALPHARETTA, GA

Velan Capital Investment Management LP reported $164,207,527 across 51 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 75.25% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001848809-26-000003

Period
2026-06-30
Reported value
$164M
Holdings
51
Top 10 weight
75.25%
New
7
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IMMXadded+345,000$3.56M
CCCCnew+570,000$2.66M
AVTXadded+139,330$2.57M
ADMAnew+250,000$2.09M
RNTXnew+1,700,000$1.77M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ESPRexited-1,720,000-$4.71M
PRAXreduced-12,000-$4.02M
CTMXreduced-420,000-$1.57M
ABVXreduced-11,370-$1.52M
VRDNreduced-81,123-$1.49M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001848809-26-000003, largest first. % of portfolio is the value over $163,207,942, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 350,666 shares; 2024Q4: 300,000 shares; 2025Q1: 185,000 shares; 2025Q2: 149,334 shares; 2025Q3: 132,805 shares; 2025Q4: 100,781 shares; 2026Q1: 100,781 shares; 2026Q2: 88,781 shares 88,781$29.7M18.21%-12,000Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 522,305 shares; 2026Q1: 492,893 shares; 2026Q2: 492,893 shares 492,893$17.7M10.82%0Timeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 312,000 shares; 2026Q1: 512,160 shares; 2026Q2: 512,160 shares 512,160$17M10.42%0Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 25,000 shares; 2025Q3: 35,000 shares; 2025Q4: 35,000 shares; 2026Q1: 740,000 shares; 2026Q2: 1,085,000 shares 1,085,000$11.2M6.85%+345,000Timeline
TARAPROTARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 574,000 shares; 2024Q4: 1,579,000 shares; 2025Q1: 1,667,800 shares; 2025Q2: 2,139,000 shares; 2025Q3: 2,139,000 shares; 2025Q4: 2,834,652 shares; 2026Q1: 2,834,652 shares; 2026Q2: 2,844,652 shares 2,844,652$10.9M6.66%+10,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 64,389 shares; 2025Q4: 67,000 shares; 2026Q1: 77,000 shares; 2026Q2: 65,630 shares 65,630$8.75M5.36%-11,370Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 83,333 shares; 2024Q4: 83,333 shares; 2025Q1: 83,333 shares; 2025Q2: 83,333 shares; 2025Q3: 83,333 shares; 2025Q4: 83,333 shares; 2026Q1: 583,333 shares; 2026Q2: 549,985 shares 549,985$8M4.9%-33,348Timeline
AVRANTERIS TECHNOLOGIES GLOBALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 700,000 shares; 2026Q2: 700,000 shares 700,000$6.89M4.22%0Timeline
EDSAEDESA BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 687,500 shares; 2025Q2: 687,500 shares; 2025Q3: 687,500 shares; 2025Q4: 687,500 shares; 2026Q1: 827,500 shares; 2026Q2: 827,500 shares 827,500$6.73M4.12%0Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 506,754 shares; 2026Q1: 446,255 shares; 2026Q2: 451,255 shares 451,255$6M3.67%+5,000Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 109,972 shares; 2025Q1: 111,972 shares; 2025Q2: 154,972 shares; 2025Q3: 263,642 shares; 2025Q4: 263,642 shares; 2026Q1: 185,122 shares; 2026Q2: 324,452 shares 324,452$6M3.67%+139,330Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 250,000 shares; 2026Q2: 255,000 shares 255,000$4.11M2.52%+5,000Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 800,000 shares; 2024Q4: 800,000 shares; 2025Q1: 400,000 shares; 2025Q2: 750,000 shares; 2025Q3: 750,000 shares; 2025Q4: 750,000 shares; 2026Q1: 750,000 shares; 2026Q2: 750,000 shares 750,000$3.9M2.39%0Timeline
HRTXHERON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,986,744 shares; 2024Q4: 6,986,744 shares; 2025Q1: 6,986,744 shares; 2025Q2: 6,986,744 shares; 2025Q3: 8,753,290 shares; 2025Q4: 8,753,290 shares; 2026Q1: 8,753,290 shares; 2026Q2: 8,753,290 shares 8,753,290$3.74M2.29%0Timeline
VRCAVERRICA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 471,559 shares; 2026Q1: 471,559 shares; 2026Q2: 471,559 shares 471,559$2.89M1.77%0Timeline
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 570,000 shares 570,000$2.66M1.63%newTimeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 352,000 shares; 2025Q4: 352,000 shares; 2026Q1: 352,000 shares; 2026Q2: 352,000 shares 352,000$2.33M1.43%0Timeline
ADMAADMA BIOLOGICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 250,000 shares 250,000$2.09M1.28%newTimeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,700,000 shares 1,700,000$1.77M1.08%newTimeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 102,000 shares; 2026Q2: 105,000 shares 105,000$1.48M0.9%+3,000Timeline
NSRXNASUS PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 359,390 shares; 2026Q2: 359,390 shares 359,390$1.26M0.77%0Timeline
PROFPROFOUND MED CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 285,710 shares; 2026Q1: 285,710 shares; 2026Q2: 170,278 shares 170,278$1.13M0.69%-115,432Timeline
JSPRJASPER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,433,828 shares; 2024Q4: 1,433,828 shares; 2025Q1: 1,433,828 shares; 2025Q2: 1,433,828 shares; 2025Q3: 2,668,395 shares; 2025Q4: 2,668,395 shares; 2026Q1: 2,668,395 shares; 2026Q2: 2,668,395 shares 2,668,395$1.12M0.69%0Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,700 shares; 2025Q3: 3,700 shares; 2025Q4: 3,700 shares; 2026Q1: 3,700 shares; 2026Q2: 3,700 shares 3,700$454K0.28%0Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 35,000 shares; 2025Q1: 75,000 shares; 2025Q2: 75,000 shares; 2025Q3: 80,000 shares; 2025Q4: 80,000 shares; 2026Q1: 540,000 shares; 2026Q2: 120,000 shares 120,000$450K0.28%-420,000Timeline
NMRANEUMORA THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 80,000 shares; 2026Q2: 230,000 shares 230,000$391K0.24%+150,000Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 97,889 shares; 2025Q1: not reported; 2025Q2: 10,000 shares; 2025Q3: 16,000 shares; 2025Q4: 16,000 shares; 2026Q1: 16,000 shares; 2026Q2: 16,000 shares 16,000$388K0.24%0Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 70,000 shares; 2025Q1: 97,000 shares; 2025Q2: 160,000 shares; 2025Q3: 160,000 shares; 2025Q4: 160,000 shares; 2026Q1: 160,000 shares; 2026Q2: 130,000 shares 130,000$350K0.21%-30,000Timeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 20,000 shares; 2025Q4: 20,000 shares; 2026Q1: 40,000 shares; 2026Q2: 40,000 shares 40,000$314K0.19%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 150,600 shares; 2025Q2: 174,600 shares; 2025Q3: 175,600 shares; 2025Q4: 151,000 shares; 2026Q1: 11,000 shares; 2026Q2: 11,000 shares 11,000$297K0.18%0Timeline
MGNXMACROGENICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 30,000 shares; 2026Q2: 60,000 shares 60,000$277K0.17%+30,000Timeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 50,000 shares; 2024Q4: 56,700 shares; 2025Q1: 59,000 shares; 2025Q2: 59,000 shares; 2025Q3: 61,000 shares; 2025Q4: 13,000 shares; 2026Q1: 26,000 shares; 2026Q2: 26,000 shares 26,000$244K0.15%0Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 25,000 shares; 2026Q2: 25,000 shares 25,000$242K0.15%0Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 181,367 shares; 2025Q1: 182,083 shares; 2025Q2: 183,083 shares; 2025Q3: 20,000 shares; 2025Q4: 15,000 shares; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares 20,000$221K0.14%0Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 130,000 shares; 2025Q4: 130,000 shares; 2026Q1: 10,000 shares; 2026Q2: 10,000 shares 10,000$219K0.13%0Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 153,500 shares; 2025Q2: not reported; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 10,000 shares; 2026Q2: 10,000 shares 10,000$212K0.13%0Timeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 6,000 shares 6,000$206K0.13%newTimeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 294,643 shares; 2026Q2: 60,000 shares 60,000$205K0.13%-234,643Timeline
KPTIKARYOPHARM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 15,000 shares; 2026Q2: 20,000 shares 20,000$195K0.12%+5,000Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 40,000 shares 40,000$194K0.12%newTimeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 86,500 shares; 2025Q3: 86,500 shares; 2025Q4: 86,500 shares; 2026Q1: 91,123 shares; 2026Q2: 10,000 shares 10,000$184K0.11%-81,123Timeline
SCYXSCYNEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 40,000 shares 40,000$163K0.1%newTimeline
QNRXQUOIN PHARMACEUTICALS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 84,849 shares; 2026Q2: 32,372 shares 32,372$157K0.1%-52,477Timeline
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 14,285 shares; 2026Q2: 14,285 shares 14,285$137K0.08%0Timeline
NSPRINSPIREMD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 904,029 shares; 2024Q4: 904,029 shares; 2025Q1: 904,029 shares; 2025Q2: 904,029 shares; 2025Q3: 2,143,698 shares; 2025Q4: 2,143,698 shares; 2026Q1: 2,099,652 shares; 2026Q2: 148,138 shares 148,138$104K0.06%-1,951,514Timeline
KLRSKALARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 18,000 shares; 2026Q2: 25,000 shares 25,000$102K0.06%+7,000Timeline
LRMRLARIMAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 18,000 shares; 2025Q1: 28,000 shares; 2025Q2: 33,000 shares; 2025Q3: 33,000 shares; 2025Q4: 33,000 shares; 2026Q1: 33,000 shares; 2026Q2: 33,000 shares 33,000$101K0.06%0Timeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 40,500 shares; 2025Q1: 45,000 shares; 2025Q2: 45,000 shares; 2025Q3: 45,000 shares; 2025Q4: 45,000 shares; 2026Q1: 45,000 shares; 2026Q2: 45,000 shares 45,000$83.7K0.05%0Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,290,323 shares; 2024Q4: 90,000 shares; 2025Q1: 90,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 100,000 shares; 2026Q2: 59,700 shares 59,700$33.1K0.02%-40,300Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 75,000 shares; 2025Q1: 75,000 shares; 2025Q2: 75,000 shares; 2025Q3: 70,000 shares; 2025Q4: 70,000 shares; 2026Q1: 70,000 shares; 2026Q2: 70,000 shares 70,000$11.5K0.01%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
TENXTENAX THERAPEUTICS INC COM NEWcall68,700$1000Knew

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ESPRESPERION THERAPEUTICS INC NE1,720,000$4.71Mshares
KZIAKAZIA THERAPEUTICS LTD135,315$1.01Mshares
ARWRARROWHEAD PHARMACEUTICALS IN6,500$408Kshares
DSGNDESIGN THERAPEUTICS INC20,000$213Kshares
PMVPPMV PHARMACEUTICALS INC73,000$90.5Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001848809-26-000003 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001848809-26-000003 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001848809-26-000002 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001848809-26-000001 Quarter ended 2025-12-312026-02-13acceptance time not in the bulk data set
13F-HR 0001848809-25-000008 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001848809-25-000005 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0000938552-25-000003 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001848809-25-000001 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001848809-24-000011 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001848809-24-000007 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001848809-24-000006 Quarter ended 2024-03-312024-05-14acceptance time not in the bulk data set
13F-HR 0001848809-24-000005 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001848809-23-000004 Quarter ended 2023-09-302023-11-13acceptance time not in the bulk data set
13F-HR 0001848809-23-000003 Quarter ended 2023-06-302023-08-11acceptance time not in the bulk data set
13F-HR 0001848809-23-000002 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001848809-23-000001 Quarter ended 2022-12-312023-02-13acceptance time not in the bulk data set
13F-HR 0001848809-22-000008 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001848809-22-000006 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001848809-22-000004 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001848809-22-000002 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set